AI summary · may contain errors
TP53-mutated CHIP in 104 CAR-T recipients is linked to lower platelet and hemoglobin levels, higher baseline CAR-HEMATOTOX scores, and inferior clinical outcomes.
- 1 cited this week
- Open access
Moving in Leukemia.
Rebuilt
AI summary · may contain errors
TP53-mutated CHIP in 104 CAR-T recipients is linked to lower platelet and hemoglobin levels, higher baseline CAR-HEMATOTOX scores, and inferior clinical outcomes.
AI summary · may contain errors
Csnk1a1 E98V in del(5q) myelodysplastic neoplasms rewires kinase signaling and metabolism, suppressing translation and cell-cycle programs while reducing mitochondrial respiration.
Newest first · last 60 days
AI summary · may contain errors
Vorasidenib produced progressive MRI tumor shrinkage in 54 grade 2 IDH1/2-mutant astrocytomas and oligodendrogliomas, with median volume reductions reaching -55.5% by cycle 18.
AI summary · may contain errors
Baseline and response reporting in myelodysplastic syndromes/neoplasms trials shows substantial variability, with baseline ANC reported in 16% of lower-risk and 23% of higher-risk studies.
AI summary · may contain errors
In 202 chronic myeloid leukemia patients treated with olverembatinib or ponatinib, the high-burden ASXL1 p.G646Wfs*12 variant is the most consistent genomic marker of inferior responses and outcomes.
AI summary · may contain errors
hAB2 CAR-T cells selectively eradicate CALRmut myeloproliferative neoplasm–sustaining stem cells in patient-derived tumor xenografts, eliminating all detectable MPN-propagating function in serial transplantation assays.
AI summary · may contain errors
In two patient-derived B-cell acute lymphoblastic leukemia cases, clonal barcoding and multiome single-cell profiling show unidirectional differentiation from an immature source cluster into differentiated progeny.
AI summary · may contain errors
In CIBMTR registry patients aged ≥50 with AML/MDS receiving allogeneic HCT, fludarabine–melphalan regimens (FM100, FM140) showed superior late overall survival versus fludarabine–busulfan (FB2), with HR 0.79 and 0.77.
AI summary · may contain errors
AML874, a selective CDK8/CDK19 inhibitor, disrupts Mediator-dependent transcription and shows subtype-specific sensitivity in FLT3-mutated AML, with strong synergy to venetoclax.
AI summary · may contain errors
FTO knockdown or pharmacologic inhibition in acute myeloid leukemia leaves m6A stoichiometry unchanged, including at MYC-specific sites, while snRNA m6Am increases markedly.
AI summary · may contain errors
Pathological mesenchymal stromal cells in MDS and sAML induce profound chromatin remodeling in NK cells, suppressing stress-response and survival programs and impairing cytotoxicity.
AI summary · may contain errors
In older patients (>60) with newly diagnosed AML, adding quizartinib to intensive chemotherapy improved overall survival only for FLT3-mutated disease (HR 0.59, 95% CI 0.37–0.93).
AI summary · may contain errors
KHSRP is the top vulnerability in therapy-persistent acute myeloid leukemia, and its depletion sensitizes AML to treatment and substantially prolongs survival in treated AML-bearing mice.
AI summary · may contain errors
In multiple myeloma cells, PP1C dephosphorylates KRAS/NRAS T148 to enable LZTR1-dependent proteasomal degradation, while KRAS A146 gain-of-function mutations resist this pathway.
AI summary · may contain errors
In 56 acute myeloid leukemia patients, AML-CAPP-Seq plasma ctDNA enabled universal MRD assessment with a median of 30.5 tracked variants per patient.
AI summary · may contain errors
Clinically relevant chronic myeloid leukemia phenotypes emerge clearly at the pseudobulk (macrostate) level despite continuous single-cell transcriptional microstates.
AI summary · may contain errors
A posttranslational mechanism that regulates RAS stability is active almost exclusively in hematologic (heme) malignancies, highlighting a RAS hotspot mutation context in leukemia and myeloma.
AI summary · may contain errors
In a phase Ib trial of AML/MDS patients (n = 14), anti-TIM3 sabatolimab plus decitabine expanded cytotoxic NK subsets and enhanced type I IFN signaling.
AI summary · may contain errors
An MPRA screen in CD34+ cells identified 87 regulatory noncoding variants across 32 CHIP-associated loci, including an MSI2 enhancer variant linked to clonal expansion of Tet2-deficient HSPCs.
AI summary · may contain errors
CEBPA-mutant Hoxb8-FL multipotent murine progenitors transplanted into syngeneic mice progress to overt myeloid neoplasm in ~12 months with 100% penetrance and fatal outcome.
AI summary · may contain errors
Adding decitabine to busulfan-cyclophosphamide conditioning before allogeneic HSCT reduces 2-year relapse incidence in adults with KMT2A-rearranged leukaemia from 29% to 12%.
AI summary · may contain errors
Excess folic acid is linked to impaired erythropoiesis in myelodysplastic neoplasms, with elevated folic acid levels and a FOLR2–IRF2BP2 pathway driving differentiation arrest in MDS mice and patients.
AI summary · may contain errors
Designing cardiovascular outcomes trials in clonal hematopoiesis of indeterminate potential (CHIP) is complicated by mutation-driven biological heterogeneity, clone-size–dependent risk, and inconsistent sequencing detection thresholds.
AI summary · may contain errors
Hematopoietic KDM6A loss in mice impairs cardiac recovery after myocardial infarction by increasing myeloid recruitment and reprogramming inflammatory, migratory, glycolytic immune states.
AI summary · may contain errors
SLF2 and SMC5 dysfunction in patient-derived hematopoietic progenitor cells is linked to premature HSC aging and predisposition to MDS, with markedly reduced xenotransplant engraftment.
AI summary · may contain errors
In MLL-AF9-transformed primary acute myeloid leukemia cells, NFE2 is a top dependency under redox stress and its knockdown sensitizes cells to GSH depletion, ferroptosis, and cytarabine.
AI summary · may contain errors
Greatwall kinase is required for acute myeloid leukaemia (AML) cell proliferation, where its loss disrupts cytokinesis via a non-canonical pathway distinct from ENSA–PP2A-B55.
AI summary · may contain errors
HDAC inhibitor–venetoclax combinations are mechanistically rational in acute myeloid leukaemia, with chidamide-based CACAG-VEN reporting overall response rates of 76.5–98.0%.
AI summary · may contain errors
In UK Biobank participants, clonal hematopoiesis of indeterminate potential (CHIP) is linked to markedly higher myeloid malignancy risk (HR = 9.56), especially when biologically older.
AI summary · may contain errors
Over 10% of women aged 55 years or older show detectable loss of X chromosome (LOX) in blood, with LOX clone size increasing significantly with age.
Journals this month
Topics moving, week to 18 Nov 2026
By field